Your Strength. Our Knowledge and Experience.

Breast cancer screening guidelines are designed to help detect breast cancer early when it is most treatable. Here’s an overview of the current recommendations for both women and men.

Breast Cancer Screening Guidelines for Women

Age to Start Screening:

• Ages 40 – 44:Women should have the option to start annual screening mammograms if they choose to do so.
• Ages 45 – 54:Annual mammograms are recommended.
• Ages 55 and Older:Women can transition to biennial (every two years) mammograms, or they may continue annual screening if they prefer. Screening should continue as long as a woman is in good health and has a life expectancy of 10 years or more.
• Clinical Breast Exam: Clinical breast exams by a healthcare provider are no longer universally recommended as part of routine screening but may still be performed based on individual patient needs.

Breast Self-Exam: Regular breast self-exams are not recommended as a primary screening tool, but being familiar with one’s breast tissue can help women notice any changes.

For Women at Higher Risk: Women with a family history of breast cancer, genetic mutations (like BRCA1 or BRCA2), or other risk factors may need to begin screening earlier (often at age 30) and consider additional imaging tests like MRI.

Breast Cancer Screening Guidelines for Men

General Recommendations: Routine screening mammograms are not recommended for men. However, awareness of breast changes is essential, as men can develop breast cancer, though it is rare.

Awareness and Self-Exams: Men should also be aware of their breast tissue and report any changes, such as lumps or changes in appearance, to a healthcare provider.

For Men at Higher Risk: Men with significant family histories of breast cancer or genetic predispositions may require more frequent monitoring and potentially earlier screening.

Summary

Breast cancer screening is crucial for early detection and successful treatment. Women should begin regular screening based on established age guidelines, while men should remain vigilant about changes in their breast tissue, especially if they are at higher risk. It’s essential for individuals to have open discussions with their healthcare providers about personal risk factors and the most appropriate screening protocols for their circumstances.

Lung cancer screening is designed to detect the disease in its early stages when treatment is most effective. Here are the current guidelines for lung cancer screening, focusing primarily on individuals at high risk.

Screening Recommendations

High-Risk Individuals:

• Age:Annual screening is recommended for adults aged 50 to 80
• Smoking History: Individuals with a 30 pack-year smoking history (smoking one pack per day for 30 years, or two packs per day for 15 years) or a comparable history of smoking need to be screened. This includes current smokers and those who have quit within the last 15 years.
• Risk Factors: Individuals with other risk factors, such as a significant family history of lung cancer or exposure to certain carcinogens (like asbestos), may also be considered for screening.
• Screening Method: The primary method recommended for lung cancer screening is low-dose computed tomography (LDCT). This technology uses lower doses of radiation than traditional CT scans and is effective in identifying early-stage lung cancers.
• Screening Intervals: If no cancer is detected, individuals should continue to receive annual LDCT screenings as long as they meet the high-risk criteria.
• Discontinuing Screening: Screening should be discontinued when an individual has not smoked for 15 yearsor if they are no longer in good health and unable to undergo treatment for lung cancer.

Importance of Screening
Lung cancer is often diagnosed at a late stage, which can impact treatment success and survival rates. Early detection through appropriate screening can significantly improve outcomes for high-risk individuals.

Discussing Screening with a Healthcare Provider

It’s essential for individuals who meet the high-risk criteria to have discussions with their healthcare providers about the benefits and risks of lung cancer screening. This conversation should also encompass personal health history and any additional risk factors that may influence the recommendation for screening.

Regular consultations and follow-up evaluations can help ensure that individuals remain informed and proactive about their lung health.

Cervical cancer screening is crucial for early detection and prevention of the disease. Here’s an overview of the current recommendations for cervical cancer screening:

General Recommendations

Age to Start Screening:

• Women Ages 21 to 29: Begin screening with a Pap test(cervical cytology) every 3 years.
• Women Ages 30 to 65: There are two screening options:
• Pap Test Alone: Every 3 years.
• HPV Test Alone: Every 5 years (preferred option).
• Pap and HPV Co-Testing: Every 5 years.

Age to Stop Screening: Women may stop cervical cancer screening at age 65if they have had regular screening with negative results in the past and are not at high risk for cervical cancer.

Frequency of Screening: Screening intervals can vary based on age, past medical history, and the type of test being used. Women should consult with their healthcare provider to determine the best schedule for screening.

Special Considerations

Women with Higher Risk: Women who have a history of cervical cancer, high-grade cervical lesions, or are immunocompromised (e.g., those with HIV) may require more frequent screening, starting earlier and continuing beyond age 65.

Post-Hysterectomy: Women who have undergone a hysterectomy (surgical removal of the uterus and cervix) for non-cancerous reasons typically do not need cervical cancer screening, unless the surgery was done for cervical cancer or pre-cancer.

Vaccination: The HPV vaccine can significantly reduce the risk of cervical cancer. Vaccination is recommended for preteens, but it is also beneficial for young adults who have not been vaccinated.

Importance of Screening

Cervical cancer screening has dramatically reduced cervical cancer rates and mortality through early detection and the ability to identify precancerous changes. Women are encouraged to maintain regular screenings and follow the guidelines to ensure their health and well-being.

Conclusion

Regular cervical cancer screening is an essential part of preventive healthcare for women. Open discussions with healthcare providers can help assess individual risk factors and tailor screening schedules appropriately.

Several screening tests are available, ranging from convenient at-home options to more comprehensive procedures performed at healthcare facilities. Your doctor will work with you to select the best method based on your age and family history.

At-Home Screening Options

These tests allow you to screen in the comfort of your home without extensive preparation, though they may carry risks of false positives.

1. At-Home Testing for Colorectal Cancer: If you are under 50, your physician may recommend at-home testing before scheduling a colonoscopy. This approach lets you complete the test without a day of prior colon preparation. However, it’s essential to note that these tests may overlook some polyps and cancers.
2. Stool DNA Test: Advances in at-home stool testing, such as Cologuard, have made it easier to conduct Fecal Immunochemical Tests (FIT). This simple test checks for blood and genetic changes without requiring extensive dietary changes.
3. Guaiac-based Fecal Occult Blood Test (gFBOT): Another home test prescribed by your doctor, gFBOT identifies hidden blood in the stool. If blood is detected, follow-up with a colonoscopy is typically necessary.

Screening at Healthcare Facilities

Screening procedures conducted in medical facilities are often the most accurate and valuable in colorectal cancer detection, allowing for the immediate removal of any suspicious polyps.

• Standard Colonoscopy: In this procedure, a colonoscope provides detailed images of your colon and allows for tissue removal if abnormalities are found. Proper preparation and sedation are necessary for successful outcomes, and studies show that regular colonoscopies can significantly reduce colorectal cancer mortality rates.
• Virtual Colonoscopy: Utilizing CT imaging to view your colon, this test usually does not require sedation but does involve bowel preparation. If potential issues arise, a standard colonoscopy may follow for confirmation.

When Should You Be Screened for Colorectal Cancer?

The American Cancer Society (ACS) has recently lowered the recommended screening age from 50 to 45 due to rising colorectal cancer rates among younger adults. Contributing factors may include dietary choices, physical inactivity, and obesity.
Recommended screening frequencies vary based on risk levels:

• Average Risk: Adults with no family history of colorectal cancer should undergo screenings every ten years.
• High Risk: Those with a family history, previous inflammatory diseases, or prior radiation exposure to the pelvic area should start screenings earlier and have them more frequently.

Lung cancer screening is designed to detect the disease in its early stages when treatment is most effective. Here are the current guidelines for lung cancer screening, focusing primarily on individuals at high risk.

Screening Recommendations

High-Risk Individuals:

• Age:Annual screening is recommended for adults aged 50 to 80
• Smoking History: Individuals with a 30 pack-year smoking history (smoking one pack per day for 30 years, or two packs per day for 15 years) or a comparable history of smoking need to be screened. This includes current smokers and those who have quit within the last 15 years.
• Risk Factors: Individuals with other risk factors, such as a significant family history of lung cancer or exposure to certain carcinogens (like asbestos), may also be considered for screening.
• Screening Method: The primary method recommended for lung cancer screening is low-dose computed tomography (LDCT). This technology uses lower doses of radiation than traditional CT scans and is effective in identifying early-stage lung cancers.
• Screening Intervals: If no cancer is detected, individuals should continue to receive annual LDCT screenings as long as they meet the high-risk criteria.
• Discontinuing Screening: Screening should be discontinued when an individual has not smoked for 15 yearsor if they are no longer in good health and unable to undergo treatment for lung cancer.

Importance of Screening
Lung cancer is often diagnosed at a late stage, which can impact treatment success and survival rates. Early detection through appropriate screening can significantly improve outcomes for high-risk individuals.

Discussing Screening with a Healthcare Provider

It’s essential for individuals who meet the high-risk criteria to have discussions with their healthcare providers about the benefits and risks of lung cancer screening. This conversation should also encompass personal health history and any additional risk factors that may influence the recommendation for screening.

Regular consultations and follow-up evaluations can help ensure that individuals remain informed and proactive about their lung health.

Prostate cancer screening guidelines are designed to help identify the disease in its early stages when it can be treated more effectively. Here’s an overview of the current recommendations:

Screening Recommendations

Age to Start Screening:

• Men at Average Risk:Screening for prostate cancer using the prostate-specific antigen (PSA) test is generally recommended to begin at age 50.
• Men at High Risk:For those at higher risk, including African American men or those with a family history of prostate cancer, screening may begin earlier, at age 45.
• Risk Factors:

Family History:A strong family history of prostate cancer (e.g., a father or brother diagnosed with the disease).

Ethnicity: African American men are at a higher risk for developing prostate cancer.

Genetic Factors: Inherited genetic mutations, such as BRCA1 or BRCA2, can increase risk.

Discussion of Screening: It is crucial for men to have an informed discussion with their healthcare provider about the risks and benefits of prostate cancer screening, including the potential for false positives and overdiagnosis. This discussion should encompass personal risk factors and overall health status.

Shared decision-making is emphasized to ensure that individuals understand the implications of screening and can make choices that align with their values and preferences.

Screening Methods:

• PSA Test:A blood test measuring the level of prostate-specific antigen. Elevated levels may indicate prostate cancer or other prostate conditions.
• Digital Rectal Examination (DRE):Although less commonly used as a standalone screening tool, a DRE may be performed alongside the PSA test to check for abnormalities in the prostate.

Follow-Up: If screening results indicate elevated PSA levels or if a DRE suggests abnormalities, further evaluation, including a biopsy, may be recommended to confirm the presence of prostate cancer.

Discontinuing Screening: For men over age 70or those with less than a 10-year life expectancy due to other health issues, the benefits of continuing routine screening may not outweigh the risks. Discussions around stopping screening should be had with healthcare providers.

Summary

Prostate cancer screening is an important health consideration for men, particularly those at higher risk. Open communication with healthcare providers can help guide decisions about when to start screening and how to proceed based on individual circumstances.

Pancreatic cancer is often diagnosed at an advanced stage, making early detection challenging. As a result, screening guidelines focus primarily on high-risk individuals rather than the general population. Here’s an overview of current recommendations for pancreatic cancer screening:

General Recommendations

• High-Risk Individuals: Screening for pancreatic cancer is recommended primarily for individuals at high risk due to specific factors:
• Family History: A strong family history of pancreatic cancer or other associated cancers (e.g., breast, ovarian, or colorectal cancer) may heighten risk. Individuals with genetic syndromes, such as BRCA2mutations, Lynch syndrome, or familial atypical multiple-mole melanoma syndrome (FAMMM), are also at increased risk.
• Chronic Pancreatitis:Long-standing inflammation of the pancreas can elevate the risk of developing cancer.
• Age and Testing: For individuals at high risk, screening usually begins between ages 40 and 50, depending on individual risk factors and family history.
• Women with BRCA mutations may start screening at age 50or younger.

Screening Methods

Imaging Tests:

• MRI (Magnetic Resonance Imaging) or Endoscopic Ultrasound (EUS): These imaging techniques are the most commonly used for pancreas cancer screening in high-risk individuals. They provide detailed images of the pancreas and can help identify cysts or tumors.
• Biomarker Testing: Research is ongoing to identify blood markers associated with pancreatic cancer, but as of now, there are no established routine blood tests for screening.

Follow-Up and Risk Management

• Regular Monitoring: Individuals at high risk should undergo regular screening every 1 to 2 years, depending on their healthcare provider’s recommendations and findings from previous screenings.
• Genetic Counseling: For individuals with a strong family history or genetic predisposition, genetic counseling can provide insights and may help guide decision-making regarding screening and preventive measures.

Conclusion

Because of the aggressive nature of pancreatic cancer and its often late-stage diagnosis, screening is primarily targeted at those identified as high risk. If you have concerns about your risk for pancreatic cancer, it’s essential to discuss them with your healthcare provider, who can help assess your risk and establish an appropriate screening plan.

Pros of Concurrent Treatment:

• Enhanced Effectiveness: Research indicates that combining chemotherapy with radiation therapy can enhance the overall effectiveness of treatment. This is particularly true for certain cancers, including brain, head and neck, gastrointestinal, bladder, and lung cancers. When these cancers are located in challenging areas of the body, concurrent treatment can improve the chances of successful outcomes.
• Coordinated Care: At El Portal Comprehensive Cancer Centers (EPCCC), our experienced team of board-certified medical oncologists and radiation oncologists work closely together to ensure that your treatment is well-coordinated. This collaborative approach helps to minimize potential interactions between therapies.

Cons of Concurrent Treatment:

• Increased Side Effects: While concurrent treatment can be more effective against cancer, it can also place added stress on your body. Patients often experience intensified side effects such as nausea, fatigue, pain, and hair loss. These heightened reactions can be challenging and require careful management.
• More Frequent Appointments: Receiving both chemotherapy and radiation at the same time typically involves more appointments in a shorter timeframe. This means additional monitoring, including scans and blood draws, which can add to the overall stress of the treatment process.

Given the potential challenges associated with concurrent treatment, many patients may find that their treatment plan recommends therapies to be administered sequentially rather than simultaneously. A comprehensive approach may include surgery, chemotherapy, radiation therapy, immunotherapy, or targeted therapy—either alone or in combination.

Neoadjuvant Therapy: When chemotherapy or radiation is administered before surgery, the goal is to shrink the tumor or eliminate cancer cells outside the primary tumor site. This is known as neoadjuvant therapy and can enhance the effectiveness of surgical intervention.

Adjuvant Therapy: Conversely, if chemotherapy or radiation is administered after surgery, it serves the purpose of targeting any residual cancer cells that may remain, thus reducing the risk of recurrence. This approach is called adjuvant therapy.

By spacing out treatments, your body has the opportunity to recover between therapies, often resulting in fewer and less severe side effects.

Conclusion

Navigating cancer treatment options can be overwhelming, and each patient’s circumstances are unique. It’s important to discuss your individual situation with your healthcare team to determine the best approach tailored to your needs. Understanding the pros and cons of concurrent treatment, as well as the benefits of sequential therapies, can empower you to make informed decisions about your care. Remember, you are not alone in this journey, and a supportive team is here to help guide you every step of the way.

Dr. Mahmoudieh has been a vital member of El Portal Comprehensive Cancer Centers since 2008, bringing over a decade of dedicated experience to patient care. Before joining our team, he served as the Director of the Prostate Brachytherapy Program at Kaiser Permanente in Sacramento and Roseville, demonstrating his leadership in advanced cancer treatments.

He earned his medical degree from the Albert Szent-Györgyi School of Medicine in Szeged, Hungary, in 1996. With a strong interest in treating head, neck, and breast cancers, Dr. Mahmoudieh specializes in cutting-edge techniques such as Image-Guided Radiation Therapy (IGRT) and Intensity-Modulated Radiation Therapy (IMRT). His expertise extends to treating cancers of the head and neck, lung, gastrointestinal tract, and prostate.

A committed professional, Dr. Mahmoudieh is a member of the American Society for Therapeutic Radiology and Oncology (ASTRO), reflecting his engagement with ongoing developments in cancer treatment and research. His compassionate approach and advanced skill set ensure that each patient receives personalized, state-of-the-art care.

Outside of his professional life, Dr. Mahmoudieh enjoys traveling with his son and daughter, as well as reading and playing racquetball, embracing a balanced and active lifestyle. His dedication to both his patients and his personal passions makes him a trusted partner in your journey toward health.

Dr. Elhanafy is a highly respected Associate Professor of Medical Physics and serves as the Chief Medical Physicist at El Portal Comprehensive Cancer Centers since July 2013. He earned his Ph.D. in Medical Physics from the University of Wisconsin, Madison—where he began his foundational training and completed his thesis—in 2013, building on his initial joining of the university in 1999.

 With specialized training in advanced radiation oncology techniques—such as Intensity-Modulated Radiation Therapy (IMRT), High-Dose Rate Brachytherapy (HDR), Stereotactic Radiosurgery (SRS), Total Body Irradiation (TBI), Quality Assurance, and Radiobiology—Dr. Elhanafy brings a wealth of expertise to patient care. His dedication to the field is evident through numerous published research articles, as well as awards recognizing his leadership in organizing conferences, training sessions, lectures, and workshops.

Beyond his impressive credentials, Dr. Elhanafy is deeply committed to advancing medical physics and ensuring the best possible outcomes for his patients. His compassionate approach, combined with his extensive knowledge, makes him a trusted partner in your cancer care journey.

Outside of his professional pursuits, he values spending quality time with his family, reflecting his genuine care and balance in life.

Dr. Ahuja is a distinguished, board-certified Medical Oncologist with extensive training in medical hematology. He has refined his expertise at renowned institutions such as Tata Memorial Hospital, UCLA School of Medicine, and Roswell Park, under the mentorship of esteemed hematologists including Dr. S.H. Advani, Dr. Michael Caligiuri, and Dr. M.J. Cline.

With over 25 years of experience in both hematology and oncology, Dr. Ahuja offers a deep well of knowledge and a compassionate approach to patient care at El Portal Cancer Center. His dedication to advancing the field is reflected through active membership in prestigious professional organizations, including the American Society of Hematology, the American Society of Clinical Oncology, the European Society of Medical Oncology, and the Indian Society of Medical and Pediatric Oncology.

A passionate researcher, Dr. Ahuja has contributed significantly to ongoing scientific advancements—serving on the NRG Breast Committee and the Rare Subtype Committee, and acting as Principal Investigator for the “CROWN” NCORP study. His commitment to clinical excellence and groundbreaking research underscores his dedication to improving outcomes for his patients.

Outside of his professional pursuits, Dr. Ahuja values spending quality time with his family, and enjoys hiking and traveling, embracing life outside the clinic with the same dedication he brings to his medical practice. His compassionate nature and extensive experience make him a trusted partner in your cancer care journey.

Dr. Crain is a highly experienced and board-certified Medical Oncologist and Hematologist with over 45 years of dedicated service in the medical field. Throughout his distinguished career, he has established himself as a leading expert in the diagnosis, treatment, and prevention of various cancers and blood disorders.

He earned his medical degree from the University of Illinois College of Medicine in 1977 and is actively affiliated with esteemed institutions, including Adventist Health St. Helena. Dr. Crain’s extensive experience spans a broad range of conditions, including small intestine and colorectal cancers, breast cancer, prostate cancer, anemia, leukemia, and lymphoma.

Beyond his clinical expertise, Dr. Crain is deeply committed to advancing medical research and improving patient care. His approach to treatment is rooted in compassion and a thorough understanding of complex medical conditions, ensuring each patient receives personalized, comprehensive care.

Recognized for his empathetic nature and unwavering dedication, Dr. Crain strives to achieve the best possible outcomes for his patients and foster a trusting, supportive environment. His lifelong commitment to the fields of oncology and hematology reflects his passion for making a meaningful difference in his patients’ lives.

Michael Kangas serves as the Director of Oncology and Diagnostic Imaging, where he spearheads initiatives that enhance revenue, profitability, productivity, and patient satisfaction within an underserved area. His leadership is instrumental in developing and guiding a highly skilled team of healthcare professionals across multiple clinics, providing comprehensive cancer care and diagnostic imaging services utilizing the most advanced technology. Michael’s commitment is rooted in delivering personalized, high-quality care to each patient, ensuring they receive the support they need throughout their journey.

With extensive expertise in Health Information Management, Electronic Medical Records (EMR), Radiation Therapy, Radiation Oncology, Clinical Operations, Healthcare Compliance, and Regulatory Standards, Michael ensures that all services meet the highest industry standards. He also focuses on monitoring performance, healthcare marketing, and supervisory skills to foster a collaborative, efficient, and patient-centered environment.

In addition to his clinical leadership, Michael actively volunteers with the Merced Cancer Society Foundation as its Executive Director. In this role, he oversees key operational and administrative functions to advance the foundation’s mission of positively impacting residents in the Central Valley. His efforts include community outreach, organizing fundraising events, and leading initiatives to expand the foundation’s support and resources for local cancer patients.

Michael’s dedication to improving healthcare and strengthening community ties highlights his unwavering commitment to healing, hope, and making a meaningful difference in the lives of those he serves.

Diagnosing Multiple Myeloma typically involves several steps:

1. Medical History and Physical Examination:
   • Your healthcare provider will start by reviewing your medical history, discussing symptoms you’ve experienced, and conducting a thorough physical examination to check for signs of the disease, such as bone tenderness or swelling.
2. Blood Tests:
   • Blood tests are essential in diagnosing Multiple Myeloma. Common tests include:
     • Complete Blood Count (CBC): Monitors levels of red blood cells, white blood cells, and platelets.
     • Blood Chemistry Tests: Assess kidney function and other vital parameters.
     • Serum Protein Electrophoresis (SPEP): Identifies abnormal proteins (monoclonal proteins) produced by myeloma cells.
     • Free Light Chain Assay: Measures the levels of free light chains in the blood and can indicate the presence of myeloma.

3. Urine Tests:
   • A 24-hour urine collection may be performed to check for Bence Jones protein, a type of light chain protein released by myeloma cells.
4. Bone Marrow Biopsy:
   • A definitive diagnosis often requires a bone marrow biopsy, where a small amount of bone marrow (usually from the hipbone) is extracted and analyzed for abnormal plasma cells.
5. Imaging Tests:
   • Imaging techniques such as X-rays, CT scans, or MRIs are used to assess bone damage or lesions caused by myeloma. These tests help identify areas of bone weakening or fractures.

While the exact cause of Multiple Myeloma remains unknown, several factors may increase the risk:

1. Age: The risk of developing Multiple Myeloma increases with age, most commonly affecting individuals over 65.
2. Gender: Men are more likely to develop Multiple Myeloma than women.
3. Race: African Americans have a higher incidence of Multiple Myeloma compared to Caucasian populations.
4. Family History: A family history of Multiple Myeloma or related plasma cell disorders may increase individual risk.
5. Certain Medical Conditions: Conditions such as monoclonal gammopathy of undetermined significance (MGUS) or other blood disorders can predispose individuals to myeloma.
6. Exposure to Chemicals: Long-term exposure to certain chemicals, such as benzene, and agricultural chemicals, may contribute to the development of myeloma.

Recognizing the signs and symptoms of Multiple Myeloma is crucial for early intervention:

1. Bone Pain: Persistent pain, particularly in the back, hips, or ribs, may indicate damage to the bones caused by myeloma lesions.
2. Fatigue: Anemia, caused by reduced red blood cell production, often leads to fatigue and weakness.
3. Frequent Infections: Compromised immune function due to myeloma can make patients more susceptible to infections.
4. Unexplained Weight Loss: Patients may experience unexplained weight loss with no changes in their regular diet or physical activity.

Treatment for Multiple Myeloma is generally tailored to individual patient needs and the disease’s specific characteristics. Here are the primary treatment options:

1. Chemotherapy: Chemotherapy remains a cornerstone of treatment for Multiple Myeloma. Regimens may include combinations such as:
   • Bortezomib (Velcade):A proteasome inhibitor that blocks protein degradation pathways in cancer cells.
   • Dexamethasone:A corticosteroid used in combination with other drugs to reduce inflammation and manage symptoms.
   • Lenalidomide (Revlimid):An immunomodulatory drug that enhances the immune response against myeloma cells.
2. Targeted Therapy: Targeted therapies focus specifically on cancerous cells, minimizing harm to normal cells:
   • Monoclonal Antibodies:Medications like daratumumab (Darzalex) are designed to target specific proteins on myeloma cells, leading to their destruction.
   • Carfilzomib (Kyprolis):A newer proteasome inhibitor used in patients with relapsed or refractory myeloma.
3. Immunotherapy: Immunotherapies use the body’s immune system to fight cancer:
   • Chimeric Antigen Receptor (CAR) T-Cell Therapy:This innovative approach involves modifying a patient’s T-cells to better recognize and attack myeloma cells. It has shown promise for some patients with difficult-to-treat myeloma.
4. Stem Cell Transplant: For eligible patients, stem cell transplant can provide an opportunity for long-term remission:
   • Autologous Stem Cell Transplant:This involves harvesting the patient’s own stem cells, administering high-dose chemotherapy to eliminate cancer cells, and then reinfusing the healthy stem cells.
5. Radiation Therapy: Radiation can be used to relieve pain or target specific areas affected by multiple myeloma, particularly in cases of localized disease or bone lesions.
6. Supportive Care: Supportive care plays a vital role in managing symptoms and improving quality of life. This may include medications for pain relief, management of anemia, hydration support, and nutritional counseling.

AUTHORIZATION REQUIRED: 

• Alignment Health Plan    
• AllCare IPA Merced (HMO/NO DERM)  
• ALLIANCE (CCAH)
• Anthem MediCAL Managed Care Prog.  
• Brand New Day-Universal Care, Inc.- Medicare 
• Calviva Health 
• Community Care IPA
• California Forensic Medical Group, Inc  
• Health Plan of San Joaquin HMO
• Kova Healthcare, Inc. IPA  
• Imperial Health Medical
• MediCAL  
• Central Valley Medical Providers IPA
• Sequoia Health IPA 
• United Healthcare (AARP)
• Sante Community Physicians  
• Tricare TriWest Healthare
• Alliance  
• Western Growers Assurance Trust  
• Central Valley Pace County Medical Services Program 
• Esperanza IPA- Medicare HMO
• Choice Program
• HealthNet CA- First Health Hill Physicians 
• Humana LaSalle Network Management IPA  
• Meritage Medical Network
• Seven Corners 

NO AUTHORIZATION REQUIRED: 

• Aetna
• Anthem
• Blue Cross of CA  
• Blue Shield of CA
• Medicare 
• UMR ACPN Network-America’s Choice PN  
• First Health Network-Cofinity Galaxy Health Network
• HealthSmart 
• CIGNA
• Anthem ACA Plans- Pathway EPO, PPO 
• BS of CA Promise Health Plan
• Medicare
• Railroad Multiplan/PHCS  
• NaphCare NX Health Network LLC d/b/a Valenz Access 
• Provider Network of America (PNOA)
• Wellcare
• WelbeHealth 

• Verify benefits, plan limits, referral, and pre-authorization requirements before your appointment.
• Bring your insurance card(s).
• Notify us of any insurance or personal information changes immediately.
• Understand your financial responsibility for co-pays, deductibles, and non-covered services.

• We verify and review your benefits.
• We help obtain necessary referrals and authorizations.
• We provide cost estimates.
• We inform you about financial assistance options.
• We bill your primary and, if authorized, secondary insurance.
• For Medicare patients, supervising physician info will be included on your claims.
• Our Financial Counselors can provide resources for you to help navigate obtaining traditional insurance coverage 

• Present your current insurance card at each visit.
• Keep us updated on insurance info.
• Pay co-pays at the time of service.
• Cover any balances remaining after insurance payments.

What is Gynecologic Cancer?

Gynecologic cancer refers to cancers affecting the female reproductive system. The five primary types include ovarian, cervical, endometrial, vulvar, and vaginal cancers. Each type presents distinct characteristics, yet early detection remains critical for effective treatment.

Types of Gynecologic Cancers

The six primary types of gynecologic cancers include:

1. Cervical:Originates in the cervix, the lower end of the uterus leading to the vagina.
2. Ovarian:Begins in the ovaries, the female reproductive glands located on either side of the uterus.
3. Uterine (Endometrial):Arises in the uterus, the organ where fetal development occurs.
4. Vaginal:Develops in the vagina, the channel between the uterus and the outside of the body.
5. Vulvar:Occurs on the vulva, the external part of the female genitalia.
6. Tubal:Begins in the fallopian tubes.

While treatment options will vary according to cancer type, tumor grade, and cancer stage, surgery is nearly always a crucial component. Many treatment plans also include chemotherapy and/or radiation therapy. At El Portal Cancer Centers, our team works collaboratively—our surgeon, medical oncologists, and radiation oncologists join forces to ensure you receive the most comprehensive and integrated care possible.

What are the Risk Factors?

All women face a risk of developing gynecologic cancers, and this risk increases with age. While some risk factors are controllable, others are not.

Commonly associated controllable risk factors include:

• Human papillomavirus (HPV) infection
• Long-term oral contraceptive use
• Being overweight or obese
• Poor nutrition
• Smoking
• Exposure to diethylstilbestrol (DES)
• Human immunodeficiency virus (HIV/AIDS) infection

In addition to making lifestyle changes—such as maintaining a balanced diet and exercising regularly—discussing your concerns with your doctor can lead to proactive measures for risk reduction, like the HPV vaccine.

Unfortunately, some risk factors are beyond your control, including age, race, and family history. It’s essential to remember that many women with risk factors never develop gynecologic cancer. If there is a family history of certain cancers, consider discussing genetic testing options with your healthcare provider.

What Symptoms Should I Watch For?

Being aware of potential symptoms can help facilitate early detection. Some symptoms include:

• Abnormal vaginal bleeding or discharge
• Pelvic pain
• Pain during intercourse
• Frequent or urgent bowel changes
• Bloating or a feeling of fullness

If you experience any of these symptoms for more than a month, we strongly recommend scheduling an appointment with your gynecologist. Regular check-ups are vital, even in the absence of symptoms.

What Should I Ask My Doctor?

Establishing an open dialogue with your doctor is crucial for understanding gynecologic cancer. Consider asking:

• What is a Pap test, and why is it necessary?
• How often should I schedule Pap tests?
• What do my Pap results mean?
• Is an HPV test appropriate for me?
• When can I discontinue Pap testing?

How are Gynecologic Cancers Treated? A treatment plan for gynecologic cancers is tailored to each individual. Surgery is generally the first step, often followed by a combination of chemotherapy and/or radiation therapy. Our specialists collaborate closely to ensure every aspect of your treatment is addressed thoroughly.

Are All Gynecologic Conditions Cancerous? Not all gynecological conditions are cancerous. Many benign conditions may resolve on their own or can be treated effectively. Examples include fibroids, ovarian cysts, and pelvic infections, each of which may require specific management based on severity.

Robotic-Assisted Surgery and Gynecologic Care

At El Portal Cancer Centers, we offer robotic-assisted surgery, a minimally invasive option that reduces recovery time and minimizes surgical trauma. This advanced approach allows for precise procedures through smaller incisions, resulting in less pain and scarring, lower infection risks, and quicker returns to daily activities.

Minimally Invasive Surgery Options

• Laparoscopic Surgery:A gold standard in gynecologic procedures, this technique involves small incisions and utilizes a camera to guide the surgeon.\
• Robotic-Assisted Surgery: A New Era in Gynecologic CareThe landscape of gynecologic surgery has transformed significantly. At El Portal Cancer Centers (EPCC), we are proud to offer robotic-assisted surgery, a forward-thinking option that allows for minimally invasive procedures with enhanced precision and improved outcomes. This advanced technique utilizes specialized robotic instruments coupled with a unique 3D high-definition view of the surgical site, empowering your surgeon to perform with remarkable accuracy.

Anemia is the most prevalent benign blood disorder, impacting more than 3 million Americans, according to the National Heart, Lung, and Blood Institute. Anemia occurs when there is a deficiency of red blood cells or hemoglobin in the blood.

Common Symptoms:

• Weakness
• Shortness of breath
• Dizziness
• Pale skin

Anemia can particularly affect women during pregnancy or their childbearing years due to increased iron demands.

Causes of Anemia:

1. Iron Deficiency Anemia: The most common type, usually caused by blood loss from heavy menstrual cycles or gastrointestinal issues, or from inadequate dietary iron. Treatment typically involves iron supplementation, either orally or intravenously.
2. Aplastic Anemia: A rare condition where the bone marrow fails to produce enough blood cells. Causes may include exposure to toxins, medications, or autoimmune disorders. Diagnosis often requires a bone marrow biopsy. Treatment may include immunosuppressive therapies or bone marrow transplantation.
3. Hemolytic Anemia: Occurs when red blood cells are destroyed faster than they can be produced. Causes range from infections to autoimmune disorders, with treatment addressing underlying causes and sometimes using corticosteroids.

Anemia Treatment depends on its cause, severity, and the individual’s overall health. Here are some common treatment options:

1. Dietary Changes: Increasing intake of iron-rich foods (e.g., red meat, beans, lentils, spinach) and foods high in vitamin B12 and folate (e.g., dairy, eggs, leafy greens).

2. Iron Supplements: Oral or intravenous iron supplements may be prescribed, especially for iron-deficiency anemia.

3. Vitamin Supplements: If the anemia is due to vitamin B12 or folate deficiency, supplements or injections may be recommended.

4. Medications: For anemia related to chronic diseases, medications such as erythropoietin-stimulating agents may be used to stimulate red blood cell production.

5. Blood Transfusions: In severe cases, a transfusion of red blood cells may be necessary to quickly increase hemoglobin levels.

6. Managing Underlying Conditions: Treating the underlying cause of anemia, such as chronic kidney disease, can alleviate symptoms.

7. Bone Marrow Stimulants: In certain cases, treatments that stimulate the bone marrow to produce more red blood cells may be indicated.

It’s essential to consult a healthcare provider for a proper diagnosis and treatment plan tailored to the individual’s specific condition and needs.T

Bleeding disorders are conditions in which the blood does not clot properly, leading to excessive bleeding. At El Portal Comprehensive Cancer Centers, our experts specialize in treating various bleeding disorders, including hemophilia and von Willebrand disease.

• Hemophilia: A genetic disorder mainly affecting males, characterized by excessive bleeding from minor injuries. Modern treatments use synthetic concentrated clotting factors administered intravenously, along with vasopressin to manage bleeding.
• Von Willebrand Disease : An inherited condition caused by a deficiency in a protein essential for blood clotting. Treatment focuses on preventing and managing bleeding episodes, often using synthetic hormones similar to vasopressin.

Treatment options for bleeding disorders like hemophilia and von Willebrand disease (vWD) focus on managing and preventing bleeding episodes. Here are common approaches for each:

Hemophilia:

1. Factor Replacement Therapy:
   • Prophylactic Treatment: Regular infusions of clotting factor concentrates (Factor VIII for Hemophilia A and Factor IX for Hemophilia B) to prevent bleeding episodes.
   • On-Demand Treatment: Administering clotting factors when a bleeding episode occurs.
2. Desmopressin (DDAVP):
   • Used for mild cases of Hemophilia A to stimulate the release of stored Factor VIII from blood vessel lining.
3. Gene Therapy:
   • Investigational treatments aim to provide a functional copy of the missing clotting factor gene, potentially offering a long-term solution.
4. Supportive Treatments:
   • Pain management and rehabilitation for joint health, along with lifestyle adjustments to prevent injury.

von Willebrand Disease (vWD):

1. Desmopressin (DDAVP):
   • The first line of treatment for many with type 1 vWD and some with type 2, as it helps increase von Willebrand factor (vWF) and Factor VIII levels in the blood.
2. Factor Replacement Therapy:
   • Concentrates containing von Willebrand factor and Factor VIII may be used for severe cases or during surgery.
3. Antifibrinolytic Agents:
   • Medications like tranexamic acid may be used to help prevent bleeding during dental procedures or other situations.
4. Avoiding Medications That Affect Clotting:
   • Recommendations to avoid aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) that can increase bleeding risk.
5. Lifestyle and Preventive Measures:
   • Education on avoiding injuries and managing heavy menstrual bleeding in women.

It’s crucial for individuals with bleeding disorders to work closely with a healthcare provider or a specialized hematologist to tailor treatment plans based on their specific needs and to manage their condition effectively.

Treatment options for blood clotting disorders aim to prevent clots from forming, manage existing clots, and reduce the risk of complications. Here are some common approaches based on different types of clotting disorders:

1. Anticoagulant Medications:

– Warfarin (Coumadin): A vitamin K antagonist used to prevent the formation of new clots and to keep existing clots from growing.

– Direct Oral Anticoagulants (DOACs): Medications such as apixaban (Eliquis), rivaroxaban (Xarelto), and dabigatran (Pradaxa) that directly inhibit specific clotting factors.

2. Antiplatelet Medications:

– Aspirin: Often used to prevent clot formation in arteries, particularly in individuals with a history of heart attacks or stroke.

– Clopidogrel (Plavix): Another antiplatelet medication that may be used alone or in combination with aspirin.

3. Thrombolytics:

– Clot Busters: Medications like alteplase (Activase) are used in emergency situations to dissolve large clots quickly, such as those causing strokes or pulmonary embolisms.

4. Compression Therapy:

– Compression Stockings: Used to improve blood flow and reduce swelling in individuals with venous thromboembolism (VTE) or chronic venous insufficiency.

5. Surgery:

– Thrombectomy: Surgical removal of a blood clot may be necessary in severe cases.

– Placement of Inferior Vena Cava (IVC) Filters: A filter may be placed in the IVC to catch clots that may travel from the legs to the lungs, particularly in patients with recurrent clots.

6. Lifestyle and Preventive Measures:

– Dietary Changes: Monitoring vitamin K intake (for patients on warfarin) and maintaining a balanced diet.

– Regular Exercise: Encouraging activity that enhances blood flow, while ensuring safety to avoid injury.

– Hydration: Staying well-hydrated to help maintain proper blood viscosity.

7. Management of Underlying Conditions:

Treating conditions that contribute to clotting disorders, such as atrial fibrillation, hormonal imbalances, or certain types of cancer.

Genetic Counseling:

For hereditary clotting disorders, genetic counseling may be beneficial for affected individuals and their families to understand risks and management strategies.

It’s essential for individuals with blood clotting disorders to work closely with a healthcare provider to develop a tailored treatment plan and to monitor their condition effectively. Regular follow-up and education about the disorder are also crucial parts of effective management.

Myelodysplastic syndromes represent a group of disorders where the bone marrow fails to produce healthy blood cells, leading to insufficient white blood cells, red blood cells, and platelets. Patients with MDS may experience:

• Increased risk of infections due to low white blood cell counts.
• Fatigue and shortness of breath from anemia.
• Excessive bleeding due to low platelet levels.

Treatment options may include blood transfusions, medications to stimulate blood cell production, or immune-suppressive therapies.

Receiving a prostate cancer diagnosis can be overwhelming, and there are important decisions to be made. It’s natural to have questions, and we are here to help you navigate your options and understand what lies ahead. You’ll learn about your cancer care team and what to expect as you embark on this journey.

What Type of Doctor Should You See First After a Prostate Cancer Diagnosis?

Typically, a urologist will perform the biopsy that confirms the presence of prostate cancer and assesses its aggressiveness. Following this initial diagnosis, we recommend scheduling a consultation with an oncologist. Our dedicated oncologists are well-versed in the latest treatment options, ensuring you receive therapies tailored specifically for you.

Your oncologist will help you understand the growth pattern of the cancer and how it may evolve moving forward. The biopsy results, combined with other diagnostic tests, will provide the necessary information to determine both the stage and grade of your prostate cancer.

Staging Prostate Cancer

Using the results from your biopsy and additional diagnostic tests, your oncologist will ascertain the stage of your prostate cancer. Further imaging or scans may be required to identify whether cancer cells have extended beyond the prostate.

Gleason Score and Grading

The Gleason score, included in your biopsy report, indicates how much the cancer cells have altered in various parts of the prostate. This grading aids in determining whether immediate treatment is necessary.

The Gleason score is a system used to grade prostate cancer based on how aggressive and likely it is to spread. It is determined by examining cancer cells under a microscope and assigning them a score from 1 to 5.

Grading:
1-2: Well-differentiated, least aggressive
3-4: Moderately differentiated
5: Poorly differentiated, most aggressive

Gleason scores are subject to interpretation and may vary slightly between pathologists. It is important to discuss your Gleason score with your healthcare provider to understand its implications and treatment options.

Preparing for Your First Oncology Appointment

Your first oncology appointment is essential for gathering important information, but it can be overwhelming. We suggest bringing a notebook or using your smartphone to take notes during the appointment. This will help you keep track of important details and any questions that arise.

We strongly encourage you to bring a friend or loved one for support. They can take notes, ask questions that might be on your mind, and provide reassurance.

Additionally, please bring your health records, including any prostate cancer test results, recent imaging scans, your insurance card, and a list of medications or supplements you’re currently taking.

Questions to Discuss with Your Oncologist

• How soon do I need to decide on a treatment plan?
• If “watchful waiting” is recommended, how often should I return for follow-up testing?
• What treatment options do you suggest when the time comes to proceed?
• What should I expect during future appointments?
• Are there lifestyle changes (in diet, exercise, rest, or stress management) I should consider?
• How should I manage any symptoms affecting my daily life?
• Are there any activities I should avoid or incorporate into my routine?
• Can I take nutritional supplements or vitamins to support my prostate health?
• Should my family and I consider genetic testing to check for hereditary risk?
• What supportive care resources are available through your practice or community organizations?

Feeling confident about your prostate cancer diagnosis and treatment plan is vital, even if it begins with watchful waiting. Many patients choose to seek a second opinion, and our oncologists are completely supportive of this decision. Insurance coverage for second opinions is often available, so we recommend contacting your insurance provider to verify your benefits before scheduling an appointment.

You Are Not Alone on Your Prostate Cancer Journey

At El Portal Comprehensive Cancer Centers, we are committed to supporting you throughout your entire journey. With convenient locations across Central California, we are here to offer you compassionate care and guidance every step of the way. Together, we will navigate this path to achieve the best possible outcome for your health and well-being.